Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT05914857

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05914857
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05914857. Randomized; single masking; primary purpose treatment. Start 2023-12-20 (anticipated); primary completion 2025-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients
Condition
Prediabetic State
Condition
Impaired Fasting Glucose
Condition
Impaired Glucose Tolerance
Intervention (Drug)
Dapagliflozin 10mg Tab
Intervention (Behavioral)
lifestyle interventions
Lead sponsor
Yangjin (class: other)
Collaborator
Peking University Third Hospital (class: other)

Record details

Record id
cardio:ct-nct05914857
Content hash
22e61c0df8e36f25d6f944e98dbe19404cafd0047f1f1dcfaac5fd70894655f5